Immunotherapy plus chemo shows promise for tough hodgkin lymphoma
NCT ID NCT03033914
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (ABVD) can improve cure rates for people with high-risk Hodgkin lymphoma. About 82 participants with untreated stage III or IV disease are enrolled. The Phase I part checks safety and side effects, while Phase II looks at how well the treatment controls the cancer over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (a drug that helps the immune system fight cancer) combined with chemotherapy drugs (doxorubicin, bleomycin, vinblastine, dacarbazine)
What this could lead to
If it works, this could improve the chance of curing high-risk Hodgkin lymphoma and reduce the risk of the cancer coming back.
What could go wrong
This is an early-phase trial (Phase I/II) with a small number of participants, so results may not apply to everyone. There are risks of side effects from both the chemotherapy and nivolumab, including immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BC Cancer (Data Collection Only)
Vancouver, V5Z4E6, Canada
-
Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States